Name
Multiple Myeloma: Exploring the Rapidly Evolving Treatment Landscape for Relapsed or Refractory Disease
Date & Time
Thursday, October 22, 2020, 4:30 PM - 5:30 PM
Description
This activity is sponsored by PTCE and supported by an educational grant from GlaxoSmithKline.
Speaker: Kathryn Maples, PharmD, BCOP, Emory Healthcare and Winship Cancer Institute
Program Description:
Multiple myeloma is often treated with 2- and 3-drug combinations, and emerging oral agents and monoclonal antibodies have rapidly advanced treatment options. Such complex drug regimens require oncology professionals to be familiar with preferred therapy options based on patient-specific characteristics. As these agents continue to expand the treatment landscape of multiple myeloma, so will the oncology care provider’s role as patient educator. Specific counseling points regarding adverse effect management, administration and dosing for combination therapies, and the importance of adherence to therapy for multiple myeloma will be reviewed.
Multiple myeloma is often treated with 2- and 3-drug combinations, and emerging oral agents and monoclonal antibodies have rapidly advanced treatment options. Such complex drug regimens require oncology professionals to be familiar with preferred therapy options based on patient-specific characteristics. As these agents continue to expand the treatment landscape of multiple myeloma, so will the oncology care provider’s role as patient educator. Specific counseling points regarding adverse effect management, administration and dosing for combination therapies, and the importance of adherence to therapy for multiple myeloma will be reviewed.
Target Audience: Oncology pharmacists, pharmacy technicians, physicians, and nurses
Type of Activity: Knowledge
Educational Objectives:
At the completion of this activity, pharmacists, physicians, and nurses will be able to:
At the completion of this activity, pharmacists, physicians, and nurses will be able to:
• Recognize approved and pipeline medications used for the treatment of relapsed or refractory multiple myeloma based on mechanisms of action
• Discuss the rationale behind the use of combination therapies for the treatment of patients with relapsed or refractory multiple myeloma
• Describe ways the oncology care team can assist in the supportive care of patients with relapsed or refractory multiple myeloma
At the completion of this activity pharmacy technicans will be able to:
• Recognize approved and pipeline medications used for the treatment of relapsed or refractory multiple myeloma based on mechanisms of action
• Discuss the rationale for use of combination therapies in the treatment of patients with relapsed or refractory multiple myeloma
• Describe ways members of the oncology care team can assist in the supportive care of patients with relapsed or refractory multiple myeloma
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (1.0 CEU) under the ACPE universal activity numbers 0290-0000-20-257-L01-P and 0290-0000-20-257-L01-T. The activity is available for CE credit on October 22, 2020.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Physicians’ Education Resource®, LLC and Pharmacy Times Continuing Education™. Physicians’ Education Resource®, LLC is accredited by the ACCME to provide continuing medical education for physicians. Physicians’ Education Resource®, LLC designates this live activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 3 Contact Hours.
Instructions for Completing the Activity and Receiving CPE Credit to receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. Credit must be requested no later than December 22, 2020. CE credit will not be issued after this date.